ELANCO ANIMAL HEALTH Reports 3.9% Increase in Total Revenue in Third Quarter of FY2023

☀️Earnings Overview

On November 7 2023, ELANCO ANIMAL HEALTH ($NYSE:ELAN) revealed their earnings results for the third quarter of FY2023 with total revenue amounting to USD 1068.0 million, a year-on-year increment of 3.9%. Simultaneously, the net income was reported as USD -1096.0 million, in comparison to the deficit of USD -49.0 million from the same quarter in the previous year.

Analysis

Analyzing ELANCO ANIMAL HEALTH’s financials with GoodWhale’s analysis, we can see that the company is strong in terms of growth, profitability and weak in asset, dividend. According to the Star Chart, ELANCO ANIMAL HEALTH has an intermediate health score of 6/10, indicating that it is likely to sustain future operations in times of crisis. We can further classify it as a ‘rhino’ type of company, which has achieved moderate revenue or earnings growth. This type of company could be of interest to different types of investors. Those looking for long-term investments may benefit from the company’s ability to sustain operations during difficult times and moderate growth potential. Risk-takers may also find it appealing due to its potentially high returns if the company’s performance continues to improve. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for ELAN. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for ELAN. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for ELAN. More…

Key Ratios Snapshot

Some of the financial key ratios for ELAN are shown below. More…

Peers

The company’s competitors include GeneFerm Biotechnology Co Ltd, Rhone Ma Holdings Bhd, and Phibro Animal Health Corp.

– GeneFerm Biotechnology Co Ltd ($TPEX:1796)

Ferm Biotechnology Co Ltd is a company that manufactures and sells biotechnology products. The company has a market cap of 2.34B as of 2022 and a return on equity of 9.05%. The company’s products are used in the healthcare, food and beverage, and industrial markets.

– Rhone Ma Holdings Bhd ($KLSE:5278)

Rhone Ma Holdings Bhd is a Malaysia-based investment holding company. The Company, through its subsidiaries, is engaged in the provision of management services, banking and financial services, and investment holding. The Company’s segments include Commercial Banking, which is engaged in the provision of banking products and services to small and medium enterprises (SMEs) and individuals; Treasury, which is engaged in the provision of foreign exchange and money market services; and Corporate Banking, which is engaged in the provision of financing solutions to SMEs and large corporations.

– Phibro Animal Health Corp ($NASDAQ:PAHC)

Phibro Animal Health Corp is a publicly traded company that focuses on animal health and nutrition. As of 2022, the company had a market capitalization of 505.49 million and a return on equity of 19.25%. Phibro Animal Health Corp was founded in 1947 and is headquartered in Teaneck, New Jersey. The company’s products include pharmaceuticals, vaccines, and nutritional supplements for livestock, poultry, and aquaculture.

Summary

ELANCO ANIMAL HEALTH reported their third quarter earnings for FY2023 on November 7th, with total revenue of USD 1068.0 million and net income of USD -1096.0 million. Despite this, the stock price rose the same day, likely due to investors’ confidence in the company’s long-term prospects. ELANCO’s cost cutting efforts appear to be paying off, and future earnings reports should be monitored closely to determine the company’s future performance. Overall, ELANCO ANIMAL HEALTH is a good investment for investors looking to capitalize on its strong fundamentals.